KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment.

Elena A Christofides, Andrzej Stankiewicz, Douglas Denham, Diego Bellido, Edward Franek, Samer Nakhle, Monika Łukaszewicz, John Reed, Victoria Cózar-León, Christine Kosch, Piotr Karaś, David Fitz-Patrick, Yehuda Handelsman, Mark Warren, Priscilla Hollander, David Huffman, Philip Raskin, Tamás Oroszlán, Michael Lillestol, Fernando Ovalle

Endocr Pract 30(9) 810-816

PMID38876181
PMCID-
DOI10.1016/j.eprac.2024.06.002
发表日期2024-06-14
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

OBJECTIVE: To compare the immunogenicity, safety, and efficacy of Gan & Lee insulin glargine (GL Glargine) with that of the originator insulin glargine (Lantus) in patients with type 1 diabetes mellitus (T1DM). METHODS: This was a phase 3, multicenter, randomized, open-label, equivalence study. Five hundred seventy-six subjects with T1DM were randomized 1:1 to receive either GL Glargine or Lantus treatment for 26 weeks. The primary end point was the percentage of subjects in each treatment group who developed treatment-induced anti-insulin antibody after baseline and up to visit week 26, which was evaluated using a country-adjusted logistic regression model. The study also compared the changes in glycated hemoglobin, and adverse events including hypoglycemia. RESULTS: The percentage of subjects positive for treatment-induced anti-insulin antibody by Week 26 was 25.8% in the GL Glargine treatment group and 25.3% in the Lantus treatment group, with a 90% confidence interval (-5.4, 6.5) of the difference in proportions that fell completely between the similarity margins (-11.3, 11.3). The least squares mean difference between treatment groups for changes in glycated hemoglobin was -0.08 (90% confidence interval: -0.23, 0.06), and the other immunogenicity and safety profiles were comparable. CONCLUSION: GL Glargine demonstrated similar immunogenicity, efficacy, and safety compared to Lantus over 26 weeks in patients with T1DM.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。